Nisa Investment Advisors’s Arcturus Therapeutics ARCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-1,422
Closed -$26.2K 2973
2025
Q3
$26.2K Sell
1,422
-17
-1% -$273 ﹤0.01% 1866
2025
Q2
$18.7K Buy
1,439
+1,149
+396% +$13.6K ﹤0.01% 1973
2025
Q1
$3.07K Sell
290
-65
-18% -$1.03K ﹤0.01% 2363
2024
Q4
$6.02K Sell
355
-68
-16% -$1.28K ﹤0.01% 2233
2024
Q3
$9.82K Sell
423
-39
-8% -$834 ﹤0.01% 2101
2024
Q2
$11.3K Sell
462
-9
-2% -$273 ﹤0.01% 2109
2024
Q1
$15.9K Buy
471
+16
+4% +$567 ﹤0.01% 1952
2023
Q4
$14.3K Buy
455
+3
+0.7% +$71 ﹤0.01% 1957
2023
Q3
$11.5K Hold
452
﹤0.01% 2144
2023
Q2
$13K Buy
452
+252
+126% +$6.86K ﹤0.01% 2209
2023
Q1
$5K Hold
200
﹤0.01% 2236
2022
Q4
$3K Hold
200
﹤0.01% 2328
2022
Q3
$4K Hold
200
﹤0.01% 2313
2022
Q2
$3K Hold
200
﹤0.01% 2309
2022
Q1
$5K Sell
200
-950
-83% -$24.2K ﹤0.01% 2305
2021
Q4
$30K Sell
1,150
-50
-4% -$2.04K ﹤0.01% 1849
2021
Q3
$57 Hold
1,200
﹤0.01% 1901
2021
Q2
$41 Buy
1,200
+200
+20% +$6.77K ﹤0.01% 1986
2021
Q1
$41 Hold
1,000
﹤0.01% 2019
2020
Q4
$43K Buy
+1,000
New +$67.7K ﹤0.01% 2011

Other funds holding ARCT

Nisa Investment Advisors's ARCT Position: Q4 2025 in Review

Nisa Investment Advisors sold out of Arcturus Therapeutics (ARCT) in Q4 2025, closing a stake of 1,422 shares — an estimated $26.2K sold.

Nisa Investment Advisors first reported a position in ARCT in Q4 2020 and held it in 20 quarters. The position peaked at $43K in Q4 2020. 120 funds tracked by Wall St. Rank hold ARCT as of Q4 2025.

  • Nisa Investment Advisors reported no remaining Arcturus Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Nisa Investment Advisors sold 1,422 Arcturus Therapeutics shares in Q4 2025, an estimated $26.2K.
  • Nisa Investment Advisors first reported a position in Arcturus Therapeutics in Q4 2020 and held it in 20 quarters.
  • Nisa Investment Advisors's Arcturus Therapeutics position peaked at $43K in Q4 2020.
  • 120 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2025.

Based on Nisa Investment Advisors's 13F filing for Q4 2025, filed 15 Jan 2026.